A Four Part, Phase I Dose-Escalation Study of the Combinations of Concurrent BKM120 and Capecitabine, or Concurrent BYL719 and Capecitabine, or Concurrent BKM120 and Capecitabine and Trastuzumab, or Concurrent BKM120 and Capecitabine and Lapatinib in Patients With Metastatic Breast Cancer

Trial Profile

A Four Part, Phase I Dose-Escalation Study of the Combinations of Concurrent BKM120 and Capecitabine, or Concurrent BYL719 and Capecitabine, or Concurrent BKM120 and Capecitabine and Trastuzumab, or Concurrent BKM120 and Capecitabine and Lapatinib in Patients With Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Buparlisib (Primary) ; Dactolisib (Primary) ; Capecitabine; Lapatinib; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 17 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 19 Jan 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top